Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Presentation to Extraordinary General Meeting

December 29, 2023December 29, 2023 Alterity Therapeutics

EGM Presentation 2023

Post navigation

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Related Posts

Quarterly Cash Flow Report

August 1, 2019August 16, 2022

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

March 6, 2018August 16, 2022

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

October 29, 2021May 23, 2023

Recent Posts

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065